Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

742P - First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies

Date

10 Sep 2022

Session

Poster session 13

Topics

Immunotherapy

Tumour Site

Presenters

John Powderly

Citation

Annals of Oncology (2022) 33 (suppl_7): S331-S355. 10.1016/annonc/annonc1058

Authors

J.D. Powderly1, O. Hamid2, M. Gutierrez3, A.S. Balmanoukian4, J. Janik5, P. Hoyle5, Z. Dong5, W. Wei5, X. Chen5, N. Bourayou5, L. Horn6

Author affiliations

  • 1 Oncology, Carolina BioOncology Institute, 28078 - Huntersville/US
  • 2 Research, The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, 90025 - Los Angeles/US
  • 3 John Theurer Cancer Center, Hackensack University Medical Center, 07601 - Hackensack/US
  • 4 Oncology Department, The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, 90025 - Los Angeles/US
  • 5 Research, Incyte Corporation, 19803 - Wilmington/US
  • 6 Hematology Oncology Department, Vanderbilt University Medical Center - Preston Cancer Research Building, 37232 - Nashville/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 742P

Background

Lymphocyte activation gene 3 (LAG-3) is a cell-surface immune checkpoint receptor that negatively regulates cell activation and proliferation. INCAGN02385 is a humanized Fc-engineered IgG1κ monoclonal antibody with selective and potent LAG-3 antagonist action against LAG-3 binding to MHC class II, leading to enhanced TCR signaling and cytokine secretion of activated T cells. This study primarily aims to determine safety and tolerability and define the MTD or PAD of INCAGN02385 monotherapy.

Methods

This phase 1, multicenter, open-label, dose-escalation study enrolled patients (pts) with advanced solid tumors who failed available therapies, were intolerant to treatment, or refused noncurative standard treatment. A 3+3 dose-escalation design was used; pts received intravenous INCAGN02385 Q2W at 1 of 5 dose levels (DL): 25 mg, 75 mg, 250 mg, 350 mg, or 750 mg. The primary endpoint was safety and tolerability; other endpoints included assessments of PK, pharmacodynamics, and preliminary efficacy per RECIST v1.1.

Results

22 pts (median age, 63 y) were enrolled, 55% were male and 82% had ECOG PS 1. Lead cancer types were lung (n=4), endometrial, breast, gastric, melanoma, and ovarian cancer (n=2 each). All pts received prior systemic therapy (64% ≥ 3 lines) and 82% had prior immunotherapy. No DLT was observed and MTD was not reached. Most common treatment-emergent adverse events (TEAEs) were fatigue (36%) and cough (27%); 1 drug-related grade 3 lymphopenia occurred at 75 mg and 1 pt in the 350-mg DL had a drug-unrelated stroke leading to discontinuation. One drug-unrelated fatal TEAE of failure to thrive occurred at 250-mg DL. INCAGN02385 trough plasma concentrations increased across cycles in all DLs, and maximum concentration and area under the serum concentration-time curve were dose-proportional across DLs. Doses ≥250 mg led to trough LAG-3 receptor occupancy of ≥90% in peripheral blood and increased markers for CD4+ T-cell proliferation. Overall disease control rate (DCR) was 27%.

Conclusions

INCAGN02385 monotherapy was generally well tolerated and exhibited linear PK. The 350 mg Q2W dose is selected for further investigation in phase 1b/2 studies in combinations with other immunotherapies (NCT04370704, NCT05287113).

Clinical trial identification

NCT03538028.

Editorial acknowledgement

Writing assistance was provided by Cory Pfeiffenberger, PhD (ICON, Blue Bell, PA, USA), and was funded by Incyte Corporation.

Legal entity responsible for the study

Incyte Corporation.

Funding

Incyte Corporation.

Disclosure

J.D. Powderly: Financial Interests, Personal, Consulting: Boxer Capital; Financial Interests, Personal, Invited Speaker, Consulting: Aavocyte; Financial Interests, Personal, Invited Speaker, Founder and Owner: Carolina BioOncology Institute, PLLC, BioCytics Inc.; Financial Interests, Personal, Ownership Interest, Founder and Owner: BioCytics Inc.; Financial Interests, Personal, Ownership Interest, Founder and Owner of phase 1 cancer research clinic.: Carolina BioOncology Institute, PLLC; Financial Interests, Personal, Founder and Owner, developing intellectual property for cellular therapies: BioCytics Inc; Financial Interests, Personal and Institutional, Invited Speaker: Bristol Myers Squibb, Cullinan, Genentech/Roche, AstraZeneca/MedImmune, EMD Serono, Macrogenics, InCyte, Top Alliance BioSciience, Seattle Genetics, AbbVie, FLX Bio, Alkermes, Arcus BioSciences, Tempest Therapeutics, Calico Life Sciences, Apros, Jounce Therapeutics, Atreca, Sequenom, Repertoire Immune Medicines, Molecular Templates, I-MAB Pharma, NexCure, Xilio Therapeutics, Immune-Onc, Trethera, Zenshine Pharma, Adagene, BJ BioScience, Fate Therapeutics, Conjupro BioTherapeutics; Financial Interests, Institutional, Funding: Precision for Medicine, MT Group, Stemcell Technologies, Replimmune, Merck, Xilis; Financial Interests, Personal And Institutional, Funding: Pioma; Financial Interests, Personal and Institutional, Invited Speaker, Also funding for contract laboratory services: Nuvation; As Founder and Owner of BioCytics Inc. developing immune cellular therapy.: BioCytics Inc.. O. Hamid: Financial Interests, Personal, Invited Speaker: BMS, Novartis, Pfizer, Sanofi / Regeneron; Financial Interests, Personal, Advisory Board: Aduro, Akeso, Amgen, Beigene, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi / Regeneron, SEAGEN, Tempus, Zelluna, Bioatla, Alkermes, Instil Bio, Iovance; Financial Interests, Institutional, Invited Speaker: Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Sanofi / Regeneron, SEAGEN, Torque, Zelluna, Rubius. M.E. Gutierrez: Financial Interests, Institutional, Funding: Incyte. A.S. Balmanoukian: Financial Interests, Institutional, Funding: Incyte. J. Janik: Financial Interests, Personal, Full or part-time Employment: Incyte. P. Hoyle: Financial Interests, Personal, Full or part-time Employment: Incyte. Z. Dong: Financial Interests, Personal, Full or part-time Employment: Incyte. W. Wei: Financial Interests, Personal, Full or part-time Employment: Incyte. X. Chen: Financial Interests, Personal, Full or part-time Employment: Incyte. N. Bourayou: Financial Interests, Personal, Full or part-time Employment: Incyte. L. Horn: Financial Interests, Institutional, Funding: Incyte.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.